Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2016

01-12-2016 | Short Communication

Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

Authors: Labidi Soumaya, Mejri Nesrine, El Benna Houda, Afrit Mehdi, Lakhdhar Sarra, Boussen Hamouda

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2016

Login to get access

Abstract

Introduction

We aim to evaluate prevalence and characteristics of CTS in routine daily practice over a 5-year period, with a review of the literature.

Methods

Patients treated with endocrine therapy (441) were retrospectively analyzed looking for CTS cases in aromatase inhibitors (219, 49.6%) and in tamoxifen (222, 50.3%) patients. We described patient’s characteristics and CTS management. We also reviewed the literature reporting CTS in aromatase inhibitors clinical trials.

Results

Six cases of CTS were diagnosed, all in patients on aromatase inhibitors given in the adjuvant setting. Prevalence was 2.7%. Median age was 54 years. CTS occurred under anastrozole in four cases and letrozole in two cases. One patient had severe intensity presentation. Median time to symptoms onset was 14 months, and resolution was obtained within 4 months after a nonsurgical treatment.

Conclusion

Aromatase inhibitor-induced CTS is rare. It should be recognized and treated in order to avoid endocrine therapy discontinuation.
Literature
1.
2.
Geoghegan JM, Clark DI, Bainbridge LC, Smith C, Hubbard R (2004) Risk factors in carpal tunnel syndrome. J Hand Surg Br. 29:315–320CrossRefPubMed
3.
Sestak I, Sapuner F, Cuzick J (2009) Aromatase inhibitors-induced carpal tunnel syndrome: results from the ATAC trial. JCO 27(30):4961–4965CrossRef
4.
Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRefPubMed
5.
Mieog JSD, Morden JP, Bliss JM, Coombes RC, van de Velde CJ (2012) Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13:420–432CrossRefPubMed
6.
Bongers FJ, Schellevis FG, van den Bosch WJ, van der Zee J (2007) Carpal tunnel syndrome in general practice (1981 and 2001): incidence and role of occupational and non occupational factors. Br J Gen Pract 57:36–39PubMedPubMedCentral
7.
Sestak I, Cuzick J, Sapunar F et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9:866–872CrossRefPubMed
8.
Colleoni M, Giobbie-Hurder A, Regan MM et al (2011) Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. JCO 29:1117–1124CrossRef
9.
Pascual E, Giner V, Arostegui A et al (1991) Higher incidence of carpal tunnel syndrome in oophorectomized women. Br J Rheumatol 30:60–62CrossRefPubMed
10.
Toesca A, Pagnotta A, Zumbo A et al (2008) Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int 32:75–79CrossRefPubMed
11.
Liu M, Wang L, Bongartz T, Hawse JR et al (2012) Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res 14(2):R41CrossRefPubMedPubMedCentral
12.
Morales L, Pans S, Verschueren K et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. JCO 26:3147–3152CrossRef
13.
Lintermans A, Laenen A, Van Calster B et al (2013) Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol 24(2):350–355CrossRefPubMed
14.
Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J (2016) Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial. JCO 34(2):139–143CrossRef
15.
Fontein DB, Seynaeve C, Hadji P et al (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257–2264CrossRefPubMed
Metadata
Title
Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice
Authors
Labidi Soumaya
Mejri Nesrine
El Benna Houda
Afrit Mehdi
Lakhdhar Sarra
Boussen Hamouda
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3190-8

Other articles of this Issue 6/2016

Cancer Chemotherapy and Pharmacology 6/2016 Go to the issue

Review Article

Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer

Original Article

Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas

Original Article

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation

Original Article

GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis

Letter to the Editor

Gota et al. on their article “the pharmacokinetics of Reditux™, a biosimilar of rituximab”

Original Article

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits